DeepMed Research

Ad5-hGCC-PADRE vaccine

Generic Name: Ad5-hGCC-PADRE vaccine

Clinical Trials

Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

Phase 1

Completed

Conditions: Colon Cancer

Interventions: Biological: Ad5-hGCC-PADRE vaccine

First Posted Date: 2013-10-30

Last Posted Date: 2025-05-02

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT01972737

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy